Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027
Topline data reported March 2022
Estimated number of individuals diagnosed with AF in U.S. in 2016.
There are currently no FDA approved drug therapies indicated for treating patients
with atrial fibrillation and heart failure with left ventricular ejection fraction (LVEF) >= 40%.
Approximate % of U.S. population with genotype that responds most favorably to Gencaro™.
Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027
Topline data reported March 2022
Estimated number of individuals diagnosed with AF in U.S. in 2016.
There are currently no FDA approved drug therapies indicated for treating patients
with atrial fibrillation and heart failure with left ventricular ejection fraction (LVEF) >= 40%.
Approximate % of U.S. population with genotype that responds most favorably to Gencaro™.
Precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient…
Cardiovascular disease is the No. 1 cause of death in the United States and a major economic burden on the healthcare system…
[+more]
Gencaro™ is a pharmacologically unique beta-blocker and mild vasodilator that we believe has potential for the treatment of atrial fibrillation…
[+more]